We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Beam Therapeutics to Report Q1 Earnings: What's in the Cards?
Read MoreHide Full Article
We expect investors to focus on Beam Therapeutics’ (BEAM - Free Report) progress in developing its pipeline candidates, which are being studied for hematological and immuno-oncology indications, when it reports first-quarter 2025 earnings.
The Zacks Consensus Estimate for the to-be-reported quarter’s top line is pegged at $15.3 million, while the same for the bottom line is pegged at a loss of $1.11 per share. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar)
Year to date, shares of Beam Therapeutics have plunged 18.7% compared with the industry’s decline of 5.8%.
Image Source: Zacks Investment Research
Factors to Note
With no marketed product in its portfolio, the company generates only collaboration revenues. BEAM’s top line is likely to have been driven by higher license and collaboration revenues in the to-be-reported quarter.
BEAM’s pipeline of gene editing therapies is based on its proprietary base editing technology.
The company is developing its leading ex-vivo genome-editing candidate, BEAM-101, in the phase I/II BEACON study for the treatment of adult patients with sickle cell disease (SCD).
In December 2024, the company announced new safety and efficacy data from the BEACON study evaluating BEAM-101 in SCD patients with severe vaso-occlusive crises. The data showed that treatment with BEAM-101 led to a robust and durable increase in fetal hemoglobin and a reduction in sickle hemoglobin.
Detailed updates from the BEACON study evaluating BEAM-101 in SCD are expected on the upcoming earnings call.
Beam Therapeutics is also expanding its genetic disease pipeline by developing BEAM-301 and BEAM-302 for treating glycogen storage disease type 1a (GSD1a) and alpha-1 antitrypsin deficiency (AATD), respectively.
Patient dosing in the phase I/II study evaluating BEAM-301 for treating GSD1a is expected to begin shortly.
Meanwhile, the FDA cleared the investigational new drug application to begin clinical studies on BEAM-302 for the treatment of AATD in the United States in March 2025. Currently, there are no approved curative treatments for the given indication.
An update from the company on the progress of the studies on these candidates is expected on the upcoming earnings call.
Earnings Surprise History
Beam Therapeutics has a mixed history of earnings surprises. The company beat on earnings in three of the trailing four quarters while missing the same on the remaining occasion, delivering an average surprise of 3.92%. In the last reported quarter, BEAM delivered an earnings surprise of 0.91%.
Our proven model does not conclusively predict an earnings beat for Beam Therapeutics this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is not the case here, as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: Beam Therapeutics has an Earnings ESP of 0.00% as both the Most Accurate Estimate and the Zacks Consensus Estimate are pegged at a loss of $1.11 per share.
Here are a few stocks worth considering from the healthcare space, as our model shows that these have the right combination of elements to beat on earnings this reporting cycle.
argenx (ARGX - Free Report) has an Earnings ESP of +10.92% and a Zacks Rank #2 at present.
argenx stock has lost 2.4% year to date. ARGX beat on earnings in two of the last four quarters and missed in the other two, delivering an average surprise of 345.11%.
CytomX Therapeutics (CTMX - Free Report) has an Earnings ESP of +38.89% and a Zacks Rank #2 at present.
CytomX Therapeutics’ shares have plunged 25.6% year to date. CTMX beat on earnings in three of the trailing four quarters and missed in the other one, delivering an average surprise of 180.70%.
Novavax (NVAX - Free Report) has an Earnings ESP of +495.75% and a Zacks Rank #3 at present.
Shares of Novavax have lost 12.1% in the year-to-date period. NVAX’s earnings beat estimates in two of the trailing four quarters and missed in the other two, delivering an average negative surprise of 0.48%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Beam Therapeutics to Report Q1 Earnings: What's in the Cards?
We expect investors to focus on Beam Therapeutics’ (BEAM - Free Report) progress in developing its pipeline candidates, which are being studied for hematological and immuno-oncology indications, when it reports first-quarter 2025 earnings.
The Zacks Consensus Estimate for the to-be-reported quarter’s top line is pegged at $15.3 million, while the same for the bottom line is pegged at a loss of $1.11 per share. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar)
Year to date, shares of Beam Therapeutics have plunged 18.7% compared with the industry’s decline of 5.8%.
Image Source: Zacks Investment Research
Factors to Note
With no marketed product in its portfolio, the company generates only collaboration revenues. BEAM’s top line is likely to have been driven by higher license and collaboration revenues in the to-be-reported quarter.
BEAM’s pipeline of gene editing therapies is based on its proprietary base editing technology.
The company is developing its leading ex-vivo genome-editing candidate, BEAM-101, in the phase I/II BEACON study for the treatment of adult patients with sickle cell disease (SCD).
In December 2024, the company announced new safety and efficacy data from the BEACON study evaluating BEAM-101 in SCD patients with severe vaso-occlusive crises. The data showed that treatment with BEAM-101 led to a robust and durable increase in fetal hemoglobin and a reduction in sickle hemoglobin.
Detailed updates from the BEACON study evaluating BEAM-101 in SCD are expected on the upcoming earnings call.
Beam Therapeutics is also expanding its genetic disease pipeline by developing BEAM-301 and BEAM-302 for treating glycogen storage disease type 1a (GSD1a) and alpha-1 antitrypsin deficiency (AATD), respectively.
Patient dosing in the phase I/II study evaluating BEAM-301 for treating GSD1a is expected to begin shortly.
Meanwhile, the FDA cleared the investigational new drug application to begin clinical studies on BEAM-302 for the treatment of AATD in the United States in March 2025. Currently, there are no approved curative treatments for the given indication.
An update from the company on the progress of the studies on these candidates is expected on the upcoming earnings call.
Earnings Surprise History
Beam Therapeutics has a mixed history of earnings surprises. The company beat on earnings in three of the trailing four quarters while missing the same on the remaining occasion, delivering an average surprise of 3.92%. In the last reported quarter, BEAM delivered an earnings surprise of 0.91%.
Beam Therapeutics Inc. Price and EPS Surprise
Beam Therapeutics Inc. price-eps-surprise | Beam Therapeutics Inc. Quote
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for Beam Therapeutics this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is not the case here, as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: Beam Therapeutics has an Earnings ESP of 0.00% as both the Most Accurate Estimate and the Zacks Consensus Estimate are pegged at a loss of $1.11 per share.
Zacks Rank: BEAM currently carries a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Stocks to Consider
Here are a few stocks worth considering from the healthcare space, as our model shows that these have the right combination of elements to beat on earnings this reporting cycle.
argenx (ARGX - Free Report) has an Earnings ESP of +10.92% and a Zacks Rank #2 at present.
argenx stock has lost 2.4% year to date. ARGX beat on earnings in two of the last four quarters and missed in the other two, delivering an average surprise of 345.11%.
CytomX Therapeutics (CTMX - Free Report) has an Earnings ESP of +38.89% and a Zacks Rank #2 at present.
CytomX Therapeutics’ shares have plunged 25.6% year to date. CTMX beat on earnings in three of the trailing four quarters and missed in the other one, delivering an average surprise of 180.70%.
Novavax (NVAX - Free Report) has an Earnings ESP of +495.75% and a Zacks Rank #3 at present.
Shares of Novavax have lost 12.1% in the year-to-date period. NVAX’s earnings beat estimates in two of the trailing four quarters and missed in the other two, delivering an average negative surprise of 0.48%.